These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33556172)

  • 1. Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
    Yamamoto M; Sanomachi T; Suzuki S; Uchida H; Yonezawa H; Higa N; Takajo T; Yamada Y; Sugai A; Togashi K; Seino S; Okada M; Sonoda Y; Hirano H; Yoshimoto K; Kitanaka C
    Neuro Oncol; 2021 Jun; 23(6):945-954. PubMed ID: 33556172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
    Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
    Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
    Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
    Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
    World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
    Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
    Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
    Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
    Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
    Bird NT; Elmasry M; Jones R; Psarelli E; Dodd J; Malik H; Greenhalf W; Kitteringham N; Ghaneh P; Neoptolemos JP; Palmer D
    Br J Surg; 2017 Mar; 104(4):328-336. PubMed ID: 28199010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
    Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R
    Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
    Farrell JJ; Elsaleh H; Garcia M; Lai R; Ammar A; Regine WF; Abrams R; Benson AB; Macdonald J; Cass CE; Dicker AP; Mackey JR
    Gastroenterology; 2009 Jan; 136(1):187-95. PubMed ID: 18992248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
    Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
    Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
    Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
    Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
    Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
    Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
    Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
    Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
    Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach.
    De Pas TM; Toffalorio F; Giovannetti E; Radice D; Russo F; Angeli I; Calamai G; Spitaleri G; Catania C; Noberasco C; Milani A; Pelosi G; Danesi R; De Braud F
    J Thorac Oncol; 2011 Apr; 6(4):768-73. PubMed ID: 21336182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.
    Kobayashi H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Ann Surg; 2012 Aug; 256(2):288-96. PubMed ID: 22580938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.